Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05743049

Collection of Circulating Biomarkers in Pancreatic Cancer

This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pancreas Cancer Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Site Pancreatic Diseases Pancreatic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Abramson Cancer Center at University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma
  • The subject must be a patient of the University of Pennsylvania
  • The subject must be able to provide informed consent
  • The subject must be 18 years of age or older

Exclusion criteria

. Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.

Treatment and study plan

Obtaining blood for analysis of various circulating biomarkers

Other

4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period

Primary outcomes

  1. To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. To create a computerized clinical data set from subjects with pancreatic cancer that contains information related to the subject's general health, disease status, treatments, and response.

    Time frame: Through study completion, an average of 1 year

  2. To integrate the data and specimens to permit the most informative clinical-biologic research platform.

    Time frame: Through study completion, an average of 1 year

Study contacts

Contact information is provided by the study sponsor or research team.

Liudmila Mazaleuskaya, PhD

CONTACT

[email protected]

267-455-9141

Mark O'Hara, MD

CONTACT

[email protected]

215-360-0919

Sponsors and collaborators

Lead sponsor

Abramson Cancer Center at Penn Medicine

Other

Registry information

Official study title

Protocol to Permit Collection of Circulating Biomarkers in Pancreatic Cancer

Important dates

Study start
2023
Primary completion
2027
Study completion
2028
First posted
Feb 24, 2023
Registry last updated
Apr 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.